CBD Market Could Grow to $3 Billion by 2021

by , in CBD (Cannabidiol)

Share: Tweet Pin Share

Supercharged Growth: Why A Market That Started From Zero Could Be Worth Nearly $3 Billion In 2021

Unless you’ve been living under a rock in the last few years, you’ve probably heard about cannabidiol or CBD.

This is the non-addictive, non-psychoactive chemical compound found in the cannabis sativa plant has been widely hailed as the new wonder drug of our time – a powerful plant-based medication that is extremely promising for a wide variety of conditions, diseases, and ailments. CBD has anti-seizure, antioxidant, neuroprotective, anti-inflammatory, analgesic, anti-tumor, anti-psychotic, and anti-anxiety properties which may aid in its development for potent pharmacotherapies in the near future.

But while CBD has quickly launched into the forefront of medicine and science, experts believe it could also be the next big thing in business as well.

Hypergrowth in the CBD market

Most people have probably noticed that the marijuana legalization movement in the U.S. has spurred huge investment in an industry that simply didn’t exist just a few years ago.

The great shift in public perception has not only allowed huge swaths of the population to gain access to a product that was once only available on the black market – it has also allowed entrepreneurship to flourish in a new and exciting industry, giving rise to a plethora of U.S.-based “cannabusinesses”. Cannabis is now viewed as The Next Great American Industry and according to market research provider, Arcview Market Research, it’s only just beginning.

In their latest State of Legal Marijuana Markets report, Arcview found that North American marijuana sales grew by an astounding 30% in 2016 to reach $6.7 billion in sales. Assuming a compound annual growth rate of 25%, they project North American sales to top $20.2 billion by 2021 as the legal market continues its rapid expansion in the U.S. and also Canada.

According to Arcview’s editor-in-chief Tom Adams, those are hypergrowth projections that draw similarities to cable television (19%) in the 1990’s and the broadband internet (29%) in the 2000’s. And a huge part of that will be fueled by the rapidly accelerating CBD market as well.

According to The CBD Report, published by The Hemp Business Journal, “the Hemp CBD market rose from a market that was barely noticeable a few years ago to $90 million in consumer sales for hemp-based CBD products in 2015.

Projections to date for 2016 indicate that the total CBD market is poised to grow 27% to reach $115 million across channels. In addition to hemp- based CBD products, HBJ estimates another $112 million in cannabis CBD products were sold through dispensaries in 2015, for a total CBD market of $202 million.

As sales of CBD products continue to increase, HBJ forecasts the entire U.S. CBD market will increase to $2.1 billion by 2020 and that $450 million of those sales will be from from hemp based sources, and the rest from marijuana sources.”

Amazingly, these projections are only focused on the U.S. CBD market. When you factor in the CAGR of the cannabis market in places like Canada, Australia, the U.K., and Europe, these numbers could be staggering.

In fact, Matt Karnes of Greenwave Advisors is even more optimistic about its growth growth prospects, saying, “In terms of the CBD market size, I estimate an almost $3 billion market by 2021.”

But a growing number of investors believe that even those lofty projections may be too conservative. Here’s why.

CBD will likely disrupt multi-billion dollar drug markets

GW Pharmaceuticals is a UK company that’s developing Epidiolex – a novel CBD treatment for severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS).

Now keep in mind, the global epilepsy drugs market alone was valued at $4.1 billion in 2015. However, these treatments have proven to be highly ineffective in controlling epilepsy syndromes. What’s worse, existing anti-epileptic drugs often have brutal side effects that can cause permanent damage to a patient’s body and mind. Because Epidiolex was developed to compete against these ineffective and harmful drugs, it has the potential to seize control of the antiepileptic drug market completely – which could quickly translate into blockbuster sales figures.

Not surprisingly, this potential upside has boosted the stock value of GW Pharmaceuticals (NASDAQ:GWPH) significantly over the last few years. From a share price of just $8.46 on June 12, 2013, the company’s stock has exploded higher – reaching a price of $136.95 per share on March 3, 2017.

That’s a gain of 1,518% in less than 4 years. Their market capitalization today (which can be viewed as the current market value of the company) is almost $3 billion.

This goes to show that even though this company loses tens of millions of dollars every year and has never turned a profit, investors are betting heavily that GW Pharmaceutical’s CBD drug will deliver blockbuster profits in the future. That upside is being priced into their stock today.

And that’s just for epilepsy.

CBD has shown immense promise for the treatment of many other conditions as well. We won’t go through the entire list, but here are just a few conditions in which researchers are investigating CBD’s potential for future drug treatment:

Remember how Matt Karnes of Greenwave Advisors believes the CBD market size will hit $3 billion by 2021?

If GW Pharmaceuticals can succeed in displacing traditional medications for epilepsy, then watch out. That could potentially clear the way for the development of CBD to combat numerous other conditions – potentially making today’s ineffective and (frankly) harmful medications obsolete.

We’ll have to wait and see.

Here at IwantmyCBD.org, we are dedicated to ensuring your right to obtain CBD legally. We are working hard to make sure CBD rich hemp oil remains a dietary supplement. To see what we are up to, sign up for the I want my CBD Newsletter. If you feel that CBD is right for you and want to join the fight to protect your access to CBD, you can help by liking us on Facebook, or following us on Twitter or Pinterest. Join us in spreading the word on CBD and let’s keep the momentum going!

I want my CBD: Top Reviewed CBD Products


Cannabitol 500mg From: HempLand USA
Rating: 100/100
Price: $99.95

Review Buy


Charlotte's Web 500mg From: CW Botanicals
Rating: 92/100
Price: $74.99

Review Buy


PLUS CBD Oil 500mg From: CannaVest
Rating: 86/100
Price: $63.95

Review Buy


RSHO 500mg From: HempMeds
Rating: 84/100
Price: $90.00

Review Buy

Article Resources

Share: Tweet Pin Share

Tags: Cannabidiol, CBD, CBD research, CBD uses, Economy, USA

Next Article:

Back To: Home, Blog, CBD Product Reviews

Follow IwantmyCBD on:

IwantmyCBD Newsletter Sign Up

CBD Product Reviews and Lab Tests


Cannabitol 500mg

HempLand USA



  • Total CBD:759mg
  • Doses:30/1ml
  • CBD Per Dose:23.7mg

Product ReviewLabs


Charlotte's Web 500mg

CW Botanicals



  • Total CBD:572mg
  • Doses:30/1ml
  • CBD Per Dose:19.2mg

Product ReviewLabs


PLUS CBD Oil 500mg




  • Total CBD:607mg
  • Doses:30/2ml
  • CBD Per Dose:20.5mg

Product ReviewLabs


Real Scientific Hemp Oil 500mg




  • Total CBD:543mg
  • Doses:30/2ml
  • CBD Per Dose:18.3mg

Product ReviewLabs

Web Statistics